KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

AbCellera Biologics (ABCL) Cost of Revenue (2020 - 2023)

Historic Cost of Revenue for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to $3.1 million.

  • AbCellera Biologics' Cost of Revenue rose 10182.29% to $3.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $14.2 million, marking a year-over-year decrease of 7865.04%. This contributed to the annual value of $12.8 million for FY2024, which is 988.01% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' Cost of Revenue is $3.1 million, which was up 10182.29% from $3.5 million recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Cost of Revenue registered a high of $44.6 million during Q1 2022, and its lowest value of $437000.0 during Q1 2020.
  • Moreover, its 4-year median value for Cost of Revenue was $3.7 million (2021), whereas its average is $9.7 million.
  • In the last 5 years, AbCellera Biologics' Cost of Revenue surged by 447894.74% in 2021 and then crashed by 9298.44% in 2022.
  • Over the past 4 years, AbCellera Biologics' Cost of Revenue (Quarter) stood at $25.5 million in 2020, then decreased by 14.25% to $21.9 million in 2021, then tumbled by 92.98% to $1.5 million in 2022, then surged by 101.82% to $3.1 million in 2023.
  • Its Cost of Revenue was $3.1 million in Q4 2023, compared to $3.5 million in Q3 2023 and $3.8 million in Q2 2023.